Zymeworks Inc. shares fell 5.20% as the stock crossed below its 5-day SMA amid positive market conditions with the Nasdaq-100 up 1.12% and S&P 500 up 0.68%.
The company reported significant success in its HERIZON-GEA-01 Phase 3 trial for Ziihera, showing a notable improvement in progression-free survival for patients with HER2-positive gastroesophageal adenocarcinoma. This success is expected to lead to future regulatory approvals and potential milestone payments of up to $440 million, with $250 million anticipated from the U.S. market. Additionally, Zymeworks has initiated a $125 million share repurchase program to enhance shareholder value while maintaining financial flexibility for growth.
These developments position Zymeworks for long-term growth, supported by a strong financial foundation with approximately $270.6 million in cash and cash equivalents, ensuring operational sustainability beyond 2028.
Wall Street analysts forecast ZYME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYME is 35.55 USD with a low forecast of 30.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast ZYME stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZYME is 35.55 USD with a low forecast of 30.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.310
Low
30.00
Averages
35.55
High
42.00
Current: 22.310
Low
30.00
Averages
35.55
High
42.00
Truist
Asthika Goonewardene
Buy
initiated
$40
2025-12-17
Reason
Truist
Asthika Goonewardene
Price Target
$40
AI Analysis
2025-12-17
initiated
Buy
Reason
Truist analyst Asthika Goonewardene initiated coverage of Zymeworks with a Buy rating and $40 price target. The firm says the company has shifted from a traditional platform-centric biotech to a royalty-focused business. Truist views zanidatamab and pasritamig as two potential blockbuster drugs that will generate "considerable" milestone and royalty income for Zymeworks. The company can also continue to leverage its leading drug development platform to create incremental value, the analyst tells investors in a research note.
Wells Fargo
Equal Weight
to
Overweight
upgrade
$25 -> $33
2025-12-12
Reason
Wells Fargo
Price Target
$25 -> $33
2025-12-12
upgrade
Equal Weight
to
Overweight
Reason
Wells Fargo upgraded Zymeworks to Overweight from Equal Weight with a price target of $33, up from $25. The firm believes the company's gastroesophageal adenocarcinoma could drive upside in the shares. Th readout could generate enthusing for Zymeworks' breast cancer opportunity, which Wells models at $1.5B and gives it a 55% probability of success.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ZYME
Unlock Now
Citizens JMP
Outperform
initiated
$32
2025-12-03
Reason
Citizens JMP
Price Target
$32
2025-12-03
initiated
Outperform
Reason
Citizens JMP initiated coverage of Zymeworks with an Outperform rating and $32 price target. The company's first internally developed product candidate, zanidatamab, was approved by the FDA, the analyst tells investors in a research note. The firm thinks Zanidatamab's second approval in gastroesophageal adenocarcinoma, expected in the second half of 2026, has a high likelihood of success.
B. Riley
Buy
maintain
$30 -> $40
2025-11-21
Reason
B. Riley
Price Target
$30 -> $40
2025-11-21
maintain
Buy
Reason
B. Riley raised the firm's price target on Zymeworks to $40 from $30 and keeps a Buy rating on the shares. Zymeworks' shift to a royalty-aggregation strategy aims to optimize future de-risked cash flows from partnered programs and the potential partnering of ZW191 in 2026, the analyst tells investors in a research note. By retaining in-house R&D, acquiring royalties rather than assets, and diversifying therapeutic exposure, the company reduces binary risk while maintaining scientific rigor, with a strengthened leadership team enhancing prospects for attractive, risk-adjusted shareholder returns, the firm says.
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
